News | February 21, 2023
Teijin and Axcelead to establish drug discovery research JV
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
Subscribe To Our Newsletter & Stay Updated
